Multiplex Immunofluorescence: A Powerful Tool in Cancer Immunotherapy

Traditional immunohistochemistry (IHC) has already become an essential method of diagnosis and therapy in cancer management. However, this antibody-based technique is limited to detecting a single marker per tissue section. Since immunotherapy has revolutionized the antineoplastic therapy, developin...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-02, Vol.24 (4), p.3086
Main Authors: Sheng, Wenjie, Zhang, Chaoyu, Mohiuddin, T M, Al-Rawe, Marwah, Zeppernick, Felix, Falcone, Franco H, Meinhold-Heerlein, Ivo, Hussain, Ahmad Fawzi
Format: Article
Language:English
Subjects:
Antibodies
antibody
Antigens
Automation
Biomarkers
Cancer
Cancer immunotherapy
Care and treatment
Cartography
Diagnosis
Drug therapy
Dyes
Fluorescence
Fluorescent antibody technique
Health aspects
Immune system
Immunofluorescence
Immunohistochemistry
Immunotherapy
Labeling
Ligands
Microscopy
multiplex
Multiplexing
New technology
Pathology
Proteins
Review
Stains & staining
Tumors
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Traditional immunohistochemistry (IHC) has already become an essential method of diagnosis and therapy in cancer management. However, this antibody-based technique is limited to detecting a single marker per tissue section. Since immunotherapy has revolutionized the antineoplastic therapy, developing new immunohistochemistry strategies to detect multiple markers simultaneously to better understand tumor environment and predict or assess response to immunotherapy is necessary and urgent. Multiplex immunohistochemistry (mIHC)/multiplex immunofluorescence (mIF), such as multiplex chromogenic IHC and multiplex fluorescent immunohistochemistry (mfIHC), is a new and emerging technology to label multiple biomarkers in a single pathological section. The mfIHC shows a higher performance in cancer immunotherapy. This review summarizes the technologies, which are applied for mfIHC, and discusses how they are employed for immunotherapy research.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms24043086